Novo Nordisk’s $2.1bn Corvidia bet faces impairment after ZEUS trial miss

Novo Nordisk A/S (NYSE: NVO; Nasdaq Copenhagen: Novo-B) has lost a major opportunity to diversify its cardiovascular portfolio after ziltivekimab failed the 6,376-patient Phase 3 ZEUS outcomes trial. The once-monthly IL-6 inhibitor lowered inflammation biomarkers as intended but produced virtually no reduction in cardiovascular death, nonfatal heart attack or nonfatal stroke, with a hazard ratio of 0.99. Novo Nordisk’s US-listed shares traded near $46.92 on July 31, down approximately 9.1%, cutting its market capitalization to about $207 billion and erasing roughly $21 billion on a simple intraday market-value comparison.

The failure will trigger a non-cash impairment charge during the third quarter, although Novo Nordisk has not disclosed its size. The company originally acquired ziltivekimab through its 2020 purchase of Corvidia Therapeutics, paying $725 million upfront and agreeing to potential total consideration of up to $2.1 billion if regulatory and commercial milestones were achieved. Novo Nordisk can absorb the financial loss without changing its adjusted 2026 operating-profit outlook, but ZEUS weakens a strategic effort to build a cardiovascular business beyond the benefits already associated with its diabetes and obesity medicines.

Why a 0.99 hazard ratio erased ziltivekimab’s cardiovascular value proposition

ZEUS was designed to determine whether directly blocking IL-6 could reduce residual cardiovascular risk among patients already receiving standard treatment. Participants had established atherosclerotic cardiovascular disease, chronic kidney disease and persistent inflammation measured by an hsCRP level of at least 2 milligrams per litre. They were randomized to receive 15 mg of ziltivekimab or placebo by subcutaneous injection once each month.

The result was unusually clear for a failed cardiovascular outcomes trial. A hazard ratio of 0.99 means event risk was almost identical between ziltivekimab and placebo. The 95% confidence interval of 0.88 to 1.11 did not suggest a persuasive trend that could support an alternative regulatory interpretation or justify describing the study as narrowly missing its endpoint.

Ziltivekimab reached its intended biological target. Novo Nordisk reported expected reductions in free IL-6 and hsCRP, confirming that the drug inhibited the inflammatory pathway around which the development programme had been constructed. The absence of clinical benefit therefore challenges the translational hypothesis rather than indicating that the dose simply failed to affect IL-6.

That distinction matters commercially. Biomarker reductions helped turn ziltivekimab into a large Phase 3 investment, but payers and regulators would have required evidence that monthly treatment prevented costly and life-threatening cardiovascular events. A medicine that lowers hsCRP without reducing heart attacks, strokes or cardiovascular deaths has little basis for approval in the ZEUS population.

The patient group appeared well chosen for testing the mechanism. Participants had a mean age of 69.5 years, and approximately 92% had hypertension, 65.7% had diabetes and 41.3% had heart failure. Their median hsCRP level was 4.5 milligrams per litre, showing persistent inflammation despite contemporary cardiovascular treatment.

ZEUS also reflected changes in standard care that may have raised the efficacy threshold. Approximately 36.8% of participants were using an SGLT2 inhibitor and 11.3% were receiving a GLP-1 receptor agonist at baseline. These medicines can improve cardiovascular or kidney outcomes in relevant populations, leaving less residual risk for an additional therapy to reduce.

The neutral result does not prove that cardiovascular inflammation is commercially irrelevant. It indicates that suppressing the IL-6 ligand with this antibody did not improve the primary outcome in patients with established vascular disease, kidney impairment and elevated inflammation. Any future use will now require a different clinical setting in which IL-6 activity plays a more decisive role.

Safety further weakens the ZEUS benefit-risk case. Overall adverse-event and serious-adverse-event rates were similar between groups, and no difference in all-cause mortality was observed. Serious infections were more frequent with ziltivekimab, creating a mechanism-related disadvantage without a corresponding reduction in cardiovascular events.

Corvidia’s $2.1 billion deal now becomes a lesson in biomarker-driven acquisition risk

Novo Nordisk acquired Corvidia Therapeutics in 2020 to obtain ziltivekimab and accelerate its expansion into cardiovascular and cardiorenal disease. The transaction included a $725 million upfront cash payment and potential total payments of as much as $2.1 billion, contingent on regulatory and sales milestones.

Novo Nordisk initially recognized approximately DKK 4.58 billion in intellectual-property rights related to ziltivekimab. The company has not disclosed the asset’s current carrying value or the amount of the coming impairment, so the accounting loss cannot yet be equated directly with either the original upfront payment or the maximum transaction value.

The impairment confirms that Novo Nordisk has reduced the programme’s estimated future economic value. It does not represent a new cash payment in the third quarter because the underlying acquisition and development spending occurred previously. Reported operating profit will be affected, while the company said the outcome will not change its previously communicated adjusted operating-profit outlook.

Novo Nordisk’s reporting policy excludes major impairment charges exceeding DKK 1 billion from adjusted operating profit because it considers them exceptional and non-recurring. The company has not confirmed whether the ziltivekimab charge will exceed that threshold, although its decision to preserve adjusted guidance indicates that the charge will be treated outside the underlying outlook.

The acquisition remains a useful example of the risk involved in buying a programme supported primarily by biomarkers. Phase 2 RESCUE data had demonstrated large reductions in hsCRP and related inflammatory or thrombotic markers, providing a strong mechanistic rationale for Phase 3. Those results were real, but the acquisition’s commercial value depended on an unproven assumption that lowering the markers would reduce cardiovascular events.

The failure may reduce future contingent payments tied to ziltivekimab approvals or sales. The company has not disclosed which Corvidia milestones have already been paid or which obligations remain outstanding, so the remaining avoided consideration cannot be calculated from public information.

Novo Nordisk is financially capable of absorbing the loss. The company generated DKK 96.8 billion in reported first-quarter sales and DKK 59.6 billion in reported operating profit, although both measures were inflated by a one-time reversal of a US 340B rebate provision. Excluding that effect, adjusted first-quarter sales were DKK 70.1 billion and adjusted operating profit was DKK 32.9 billion.

Research and development costs reached approximately DKK 10.3 billion during the first quarter, and free cash flow totaled DKK 12.8 billion. Ziltivekimab’s impairment is therefore significant for portfolio evaluation but does not create an immediate liquidity problem or threaten Novo Nordisk’s ability to fund other late-stage programmes.

The larger consequence concerns capital allocation. Novo Nordisk is investing heavily to broaden its pipeline while facing increasing competition and pricing pressure in obesity and diabetes. A failed acquired asset reduces the return generated by earlier business-development spending and raises the standard for future deals based on early biological evidence.

HERMES and ARTEMIS keep ziltivekimab alive but now carry a steeper probability discount

Novo Nordisk will continue the Phase 3 HERMES and ARTEMIS cardiovascular outcomes trials. HERMES is evaluating ziltivekimab in heart failure, while ARTEMIS is studying patients following an acute myocardial infarction. Both are expected to report results during the first half of 2027.

Continuing the trials is scientifically defensible because their disease settings differ from ZEUS. HERMES is testing whether inflammation reduction improves outcomes in heart failure with preserved or mildly reduced ejection fraction. ARTEMIS evaluates treatment after an acute heart attack, when inflammation may influence tissue injury, healing and subsequent cardiac remodeling.

Stopping either study solely because ZEUS failed could waste data already accumulated and prevent Novo Nordisk from learning whether IL-6 inhibition works in a more biologically concentrated setting. The company has not reported any independent safety recommendation requiring the remaining trials to stop.

Commercial expectations should nevertheless be reduced. ZEUS was the first major Phase 3 validation of ziltivekimab’s mechanism and was conducted in a population specifically selected for elevated inflammation. The complete absence of cardiovascular benefit makes it harder to assume that the same antibody will succeed elsewhere merely because the disease label changes.

The higher rate of serious infections will also be examined closely in HERMES and ARTEMIS. Heart-failure patients are frequently older and medically vulnerable, while patients recovering from an acute heart attack may face complications that make infection risk clinically consequential. A positive result in either trial will need to provide enough benefit to offset the immune-suppression signal.

The remaining studies now function as recovery options rather than independent programmes valued on their original probabilities. Positive HERMES or ARTEMIS data could preserve part of the Corvidia acquisition value and re-establish a path toward regulatory submission. Two additional failures would likely end the major cardiovascular programme and could require a further reassessment of any remaining ziltivekimab value.

The timing creates a relatively defined period of uncertainty. Novo Nordisk expects both readouts within roughly one year, limiting the need to support the programme indefinitely without decisive evidence. The company can therefore continue gathering data while assigning less internal and external value to the asset.

Novo Nordisk can absorb ZEUS financially, but cardiovascular diversification has weakened

Novo Nordisk’s shares fell approximately 9.1% to $46.92 during July 31 trading, with intraday volume approaching 19.4 million shares. The decline reduced its market capitalization to about $207 billion and suggests investors had assigned meaningful value to ziltivekimab, its cardiovascular diversification strategy or both.

The reaction is larger than the direct accounting impact disclosed by the company. Novo Nordisk confirmed that the impairment will not change adjusted 2026 operating-profit guidance, meaning current-year underlying earnings expectations remain intact. The stock movement instead reflects lost future revenue potential and a lower probability that ziltivekimab will become a new commercial franchise.

Novo Nordisk’s cardiovascular strategy is broader than one molecule. The company continues to generate cardiovascular evidence for semaglutide and is advancing other programmes involving heart failure, atherosclerotic disease and related metabolic conditions. ZEUS does not affect approved GLP-1 products or the cardiovascular benefits already demonstrated in separate semaglutide trials.

The failure does weaken the argument that Novo Nordisk can readily convert its metabolic-disease position into a separate cardiovascular pipeline through external acquisitions. Ziltivekimab was intended to provide a non-GLP-1 mechanism and establish a presence in inflammation-driven cardiovascular medicine. Its first outcomes trial has instead shown that successful target engagement may still produce no patient benefit.

The result also arrives while Novo Nordisk is managing weaker underlying financial growth. Adjusted first-quarter sales declined 4% at constant exchange rates, and adjusted operating profit declined 6%, reflecting lower realized prices despite continued GLP-1 volume growth. The company raised its 2026 guidance in May, but it still expected adjusted sales and operating-profit growth to range from negative 4% to negative 12% at constant exchange rates.

In that environment, pipeline failures receive greater scrutiny because investors are looking for new growth engines beyond the current obesity and diabetes portfolio. Ziltivekimab had offered a potentially large chronic-treatment opportunity among patients at high risk of expensive cardiovascular events.

Novo Nordisk retains the financial strength to continue HERMES, ARTEMIS and its broader research portfolio without an emergency change in strategy. The more difficult issue is opportunity cost. Capital, scientific resources and management attention committed to ziltivekimab could otherwise have supported programmes with stronger clinical differentiation.

ZEUS therefore represents more than an isolated trial miss. It removes the broadest commercial pathway for a drug acquired in a transaction valued at up to $2.1 billion, triggers an accounting impairment and reduces confidence in two remaining trials using the same mechanism. Novo Nordisk can absorb the loss, but investors will now require direct outcome evidence before assigning substantial value to the rest of the ziltivekimab programme.

Key takeaways from the ZEUS failure and Novo Nordisk’s investment outlook

• Ziltivekimab produced a hazard ratio of 0.99 in ZEUS, showing virtually no reduction in cardiovascular death, nonfatal heart attack or nonfatal stroke.
• The drug successfully lowered free IL-6 and hsCRP, confirming target engagement while demonstrating that biomarker improvement did not translate into clinical value.
• Novo Nordisk shares fell approximately 9.1% to $46.92, erasing roughly $21 billion in market capitalization on an intraday comparison.
• The company will record a non-cash impairment during the third quarter but has not disclosed the charge or the asset’s remaining carrying value.
• Novo Nordisk paid $725 million upfront for Corvidia Therapeutics, with potential total consideration of up to $2.1 billion linked to future milestones.
• Serious infections occurred more frequently with ziltivekimab, leaving the ZEUS population with additional risk and no demonstrated cardiovascular benefit.
• HERMES and ARTEMIS will continue in heart failure and post-heart-attack populations, with both readouts expected during the first half of 2027.
• The neutral result materially lowers confidence in the remaining trials even though their patient populations and biological settings differ from ZEUS.
• Novo Nordisk can absorb the impairment without changing its adjusted 2026 operating-profit outlook or creating an immediate liquidity problem.
• The strategic damage is greater than the near-term earnings impact because ZEUS weakens Novo Nordisk’s effort to build a non-GLP-1 cardiovascular franchise.